Allergan ( AGN), the maker of the wrinkle-fighting injection Botox, provided 2006 earnings guidance that gave the company's shares a lift Monday. The company says it expects to report earnings of 80 cents to 81 cents a share in the first quarter ending this Friday. For the first time, the earnings include costs related to stock-options expensing, which in the first quarter should amount to about 4 cents a share. Allergan also forecast sales of $600 million to $610 million for the quarter, not including sales from Inamed, a maker of breast implants that the company acquired last week. For the full year, the company is projecting earnings between $3.56 and $3.62 a share, including costs of 20 cents a share for stock-options expensing. Total sales are expected to be between $2.8 billion and $2.95 billion. Of that, $870 million to $905 million will likely be from Botox. The company expects between $180 million and $200 million in sales of breast implants and related products and $130 million to $140 million in sales of its obesity products. Allergan believes the Inamed deal will have a neutral effect on its earnings for this year, but the acquisition should add to its profits starting in 2007. Allergan says it's implementing a 100-day integration plan in which the company aims to combine and restructure the merged operation. Earnings guidance for the first quarter excludes estimated charges of $110 million to $115 million related to the Inamed acquisition, the company says. Allergan's shares were up $1.30, or 1.2%, to $113.22 Monday morning.